Rituximab vs Ocrelizumab in Patients With Relapsing–Remitting MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 2023 Jun 12;[EPub Ahead of Print], I Roos, S Hughes, G McDonnell, CB Malpas, S Sharmin, C Boz, R Alroughani, S Ozakbas, K Buzzard, O Skibina, A van der Walt, H Butzkueven, J Lechner-Scott, J Kuhle, M Terzi, G Laureys, L Van Hijfte, N John, P Grammond, F Grand'Maison, A Soysal, AV Jensen, PV Rasmussen, KB Svendsen, I Barzinji, HH Nielsen, T Sejbæk, S Prakash, MLM Stilund, A Weglewski, NM Issa, M Kant, F Sellebjerg, O Gray, M Magyari, T KalincikFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.